The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels. According to the recipient fact sheet, the chance of ITP is “very low,” with symptoms in most cases occurring within 42 days after vaccination. FDA said it continues to monitor the level of potential excess risk with the Centers for Disease Control and Prevention. Individuals with a history of ITP should discuss the risk with their health care provider and the potential need for platelet monitoring after vaccination, the fact sheets note. 

Related News Articles

Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…
Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…
Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…